Most herbs promoted for prostate cancer have shown intriguing activity in lab dishes and animal studies, but very few have held up in rigorous human trials. The gap between killing cancer cells in a petri dish and shrinking tumors in a living person is enormous, and that gap defines the state of herbal prostate cancer research today. Some compounds, like green tea polyphenols and pomegranate extract, have made it to randomized placebo-controlled trials with mixed or disappointing results. Others remain stuck at the preclinical stage, generating excitement in cell culture but offering little clinical certainty. What follows is a look at the herbs that have attracted the most scientific attention and what the evidence actually supports.
More Than Half of Prostate Cancer Patients Already Use These Products
Before diving into individual herbs, it is worth understanding the scale of use. A large study following prostate cancer patients over two decades found that about 56% reported using some form of complementary or alternative medicine, with multivitamins and omega-3 fatty acids being the most popular choices. Between the late 1990s and mid-2010s, use among prostate cancer patients increased by roughly 128%. Users tended to be college-educated, higher-income, and living in the western or midwestern United States.1PubMed Central. Trends in Complementary and Alternative Medicine Use among Patients with Prostate Cancer That means the question isn’t whether men with prostate cancer are using herbal products; most of them are. The real question is whether any of these products do what patients hope.
Green Tea Extract
Green tea catechins, particularly a compound called EGCG (epigallocatechin gallate), have been among the most studied plant-derived substances in prostate cancer research. The logic is straightforward: populations that drink a lot of green tea seem to have lower prostate cancer rates, and EGCG has demonstrated anti-cancer effects in cell and animal studies. But translating that into a treatment has proven difficult.
One clinical trial gave a concentrated green tea extract called Polyphenon E (PolyE) to men on active surveillance for early-stage prostate cancer. The researchers found that PSA (prostate-specific antigen, a marker doctors use to track prostate cancer progression) dropped by about 0.87 ng/mL in the green tea group compared to placebo, a statistically significant difference.2PubMed Central. Green tea extract for prevention of prostate cancer progression in patients on active surveillance That sounds promising, but a systematic review and meta-analysis that pooled results from multiple randomized trials told a more sobering story: overall, green tea did not produce a significant change in PSA levels. The picture got more complicated in subgroup analysis, where a significant PSA reduction appeared in U.S. study populations but not in studies conducted elsewhere.3PubMed. The effect of green tea on prostate specific antigen (PSA): A systematic review and meta-analysis of randomized controlled trials That geographic inconsistency raises questions about whether differences in diet, genetics, or study design are driving the result rather than the tea itself.
The honest read on green tea extract is that it is safe for most people at moderate doses, and some individual trials look encouraging, but pooled data has not confirmed a reliable effect on prostate cancer markers. It remains one of the more promising candidates, but “promising” and “proven” are not the same thing.
Pomegranate
Pomegranate juice and extract attracted heavy interest after early uncontrolled studies suggested they could slow rising PSA in men who had already been treated for prostate cancer. In one phase II trial, men who took pomegranate extract saw their PSA doubling time (a measure of how quickly the cancer marker increases, where longer is better) stretch from a median of about 12 months at baseline to roughly 18 months after treatment. Nearly 43% of patients saw their doubling time more than double.4PubMed Central. A Review of Pomegranate in Prostate Cancer5Prostate Cancer and Prostatic Diseases. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer The researchers themselves cautioned that without a placebo group, it was impossible to know how much of that improvement was real.
That caution turned out to be warranted. When a larger, placebo-controlled phase III trial was finally conducted, the pomegranate extract group did not show a statistically significant slowing of PSA doubling time compared to placebo. The placebo group itself saw its PSA doubling time increase from about 11 months to nearly 16 months, illustrating how powerfully regression to the mean and the placebo effect can mimic a real treatment response.6Prostate Cancer and Prostatic Diseases. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer A preplanned subgroup analysis did find a benefit among men carrying a specific genetic variant (the MnSOD AA genotype), hinting that pomegranate might work for a biologically defined subset of patients rather than broadly.4PubMed Central. A Review of Pomegranate in Prostate Cancer That genetic angle is interesting but has not been confirmed in a follow-up trial.
Curcumin
Curcumin, the bright-yellow compound in turmeric, has generated a staggering volume of laboratory research. Reviews have cataloged its ability to interfere with multiple cancer-related signaling pathways in prostate cancer cells, including pathways that control cell survival, inflammation, and the androgen receptor that drives many prostate cancers.7Prostate International. Therapeutic potentials of curcumin in prostate cancer: a comprehensive review of pathways and clinical prospects On paper, curcumin looks like a multi-target wonder drug.
The catch is bioavailability. Curcumin is notoriously difficult for the body to absorb and use. When you eat turmeric or take a curcumin capsule, the vast majority of the compound passes through your gut without reaching the bloodstream in meaningful concentrations. Newer formulations using piperine (from black pepper) or lipid-based delivery systems improve absorption somewhat, but even with those tricks, achieving the concentrations that kill cancer cells in a lab would require doses far beyond what’s practical or safe. The Society of Integrative Oncology has listed curcumin among supplements with the best suggestions of benefit in cancer care, but that recommendation is about general supportive use, not as a standalone treatment for prostate cancer.8SAGE Journals / Integrative Cancer Therapies. Integrating dietary supplements into cancer care
Soy Isoflavones and Genistein
Soy-derived compounds, particularly genistein, have been studied partly because prostate cancer rates are lower in East Asian countries where soy intake is high. In the lab, genistein has been shown to affect gene expression in prostate cancer cells. At physiologically achievable concentrations, it reduced methylation of the estrogen receptor beta promoter in certain prostate cancer cell lines and inhibited cell growth, effects that were blocked when the estrogen receptor was specifically antagonized.9PubMed Central. Genistein Increases Estrogen Receptor Beta Expression in Prostate Cancer via Reducing its Promoter Methylation
Clinical trials, however, have been underwhelming. A study giving men with localized prostate cancer high doses of soy isoflavones for six months found that while serum levels of genistein and daidzein did increase significantly, PSA levels did not change.10PubMed Central. Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer A separate randomized, placebo-controlled trial of short-term soy isoflavone supplementation similarly found no significant changes in PSA, testosterone, estrogen, or cholesterol compared to placebo.11PLoS ONE. Short-Term Soy Isoflavone Intervention in Patients with Localized Prostate Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial Eating soy as part of a balanced diet is perfectly reasonable, but concentrated soy supplements have not demonstrated clinical benefit for men with prostate cancer.
Milk Thistle
Milk thistle (Silybum marianum) contains a group of compounds collectively called silymarin, with silibinin being the most studied. Research has shown silymarin can interfere with cell cycle progression and promote programmed cell death in cancer cells while also exhibiting anti-inflammatory and anti-metastatic properties.12PubMed Central. Multitargeted therapy of cancer by silymarin Some researchers have proposed it could serve as an adjunct to conventional chemotherapy and radiation to reduce their side effects.
Lab work has gone further and broken silymarin down into its individual components to see which ones matter most. Among these, isosilybin B emerged as the most consistently potent suppressor of prostate cancer cell growth and PSA secretion. Isosilybin A and isosilybin B together were the most effective at reducing PSA output from androgen-dependent prostate cancer cells, suggesting that an extract enriched for these specific components might have more clinical potential than the crude silymarin mixture found in most supplements.13PubMed. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells The problem, once again, is that these findings come from cell culture work. Clinical trial data for milk thistle in prostate cancer patients is essentially nonexistent.
Saw Palmetto, Lycopene, and Stinging Nettle
Several other herbs and plant-derived compounds appear regularly in prostate health discussions. Saw palmetto is the most well-known, widely used for benign prostate enlargement. It has shown the ability to inhibit 5-alpha reductase, the enzyme that converts testosterone to its more potent form (DHT), in animal models and in prostate cancer cell lines.14PubMed Central. Effect of Saw Palmetto Supplements on Androgen-Sensitive LNCaP Human Prostate Cancer Cell Number and Syrian Hamster Flank Organ Growth Since prescription drugs that block this same enzyme are used in prostate cancer management, the interest in saw palmetto makes logical sense. But its effects in clinical settings have been studied primarily for urinary symptoms, not for cancer treatment, and the evidence for a cancer-specific benefit in humans remains thin.
Lycopene, the red pigment in tomatoes, has attracted attention because epidemiological studies have linked higher tomato intake with lower prostate cancer risk. Cell studies show that lycopene can reduce insulin-like growth factor 1 (IGF-1) levels in prostate cancer cells in a time- and dose-dependent manner.15PubMed Central. The Protective Effect of Lycopene on Prostate Growth Inhibitory Efficacy by Decreasing Insulin Growth Factor-1 in Indonesian Human Prostate Cancer Cells Since IGF-1 can promote cancer cell growth, this is a plausible mechanism. However, like many of these compounds, the clinical trial picture has not delivered the clear results that cell studies promised.
Stinging nettle (Urtica dioica) rounds out the list of commonly discussed herbs. A review examining its anticancer properties described chemo-preventive activity against prostate, breast, and colon cancers in laboratory settings, alongside anti-inflammatory and antidiabetic effects.16PubMed Central. Urtica dioica: Anticancer Properties and Other Systemic Health Benefits from In Vitro to Clinical Trials Its use in traditional European herbal medicine for prostate and urinary complaints is longstanding, but the jump to cancer treatment remains unsupported by controlled human studies.
The PC-SPES Scandal and What It Reveals About Herbal Combinations
The story of PC-SPES is one of the most instructive episodes in herbal prostate cancer research. PC-SPES was an herbal blend of seven Chinese herbs plus saw palmetto that gained a devoted following among men with advanced prostate cancer in the late 1990s. Clinical results looked genuinely impressive. In a phase II trial, PSA declines of 50% or more were seen in 40% of patients taking PC-SPES, with a median time to progression of 5.5 months.17PubMed. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer
Then it all fell apart. California health authorities found warfarin, a prescription blood thinner, in the product. Independent scientists detected diethylstilbestrol (DES), a synthetic estrogen once used as an actual drug to treat prostate cancer.18JNCI: Journal of the National Cancer Institute. Contamination of PC-SPES Remains a Mystery Multiple lots were found to contain DES at levels ranging from a trace amount to over 3% of the dose used in the trial’s DES comparison arm. Ethinyl estradiol, another synthetic estrogen, was also detected.17PubMed. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer The product was pulled from the market, and the clinical activity that had made PC-SPES famous was almost certainly due to the undeclared pharmaceutical drugs it contained, not the herbs.19PubMed. Herbal composition PC-SPES for management of prostate cancer: identification of active principles
PC-SPES became a textbook example of why unregulated herbal supplements can be dangerous and why apparent clinical benefits always need a careful look at what is actually in the bottle.
Zyflamend and Newer Combination Formulas
Zyflamend, a polyherbal supplement containing extracts from rosemary, turmeric, ginger, holy basil, green tea, and several other plants, has taken a more careful route than PC-SPES. In a small phase I trial involving men with high-grade prostatic intraepithelial neoplasia (a precancerous condition), 18 months of Zyflamend treatment produced no serious adverse events. Nearly half of the participants saw PSA drop by 25 to 50%, and 60% of those who had a follow-up biopsy showed benign tissue. The researchers also noted a reduction in C-reactive protein, a marker of inflammation, and decreased activity of the inflammatory molecule NF-kappa-B in prostate tissue.20PubMed. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial
Lab studies have added mechanistic detail, showing that Zyflamend can suppress androgen receptor signaling and may work synergistically with the anti-androgen drug bicalutamide.21PubMed. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth Further research has explored the energy-sensing pathway AMPK as a target, finding that Zyflamend activates this pathway through a specific mechanism dependent on the tumor suppressor LKB1.22PubMed Central. Concurrent regulation of LKB1 and CaMKK2 in the activation of AMPK in castrate-resistant prostate cancer by a well-defined polyherbal mixture with anticancer properties These are provocative findings, but the human data comes from a small, single-arm trial with no placebo group. Without a controlled comparison, the PSA reductions and biopsy improvements could reflect the natural variability of early-stage disease.
Your Gut Bacteria May Determine Whether These Herbs Work for You
One of the more interesting recent threads in this field is the role of gut microbiota. Many plant polyphenols, the compounds thought to be responsible for the anti-cancer effects of green tea, pomegranate, and similar herbs, are not well absorbed in their original form. Instead, gut bacteria break them down into smaller metabolites that are actually absorbed into the bloodstream. For example, the ellagitannins in pomegranate and certain herbs like willowherb (Epilobium) are transformed by gut microbiota into compounds called urolithins. Urolithin C has shown strong anti-proliferative effects against prostate cancer cells and reduced PSA secretion in lab settings.23PubMed. Extracts from Epilobium sp. herbs, their components and gut microbiota metabolites of Epilobium ellagitannins, urolithins, inhibit hormone-dependent prostate cancer cells-(LNCaP) proliferation and PSA secretion
The bidirectional relationship between dietary polyphenols and gut bacteria has been shown to contribute meaningfully to the impact of these compounds on prostate health.24PubMed. Dietary polyphenol and microbiota interactions in the context of prostate health Similarly, the main circulating metabolites of green tea catechins are valerolactones produced by gut bacteria, not the catechins themselves.25PubMed. The Activity of Urolithin A and M4 Valerolactone, Colonic Microbiota Metabolites of Polyphenols, in a Prostate Cancer In Vitro Model This means two people taking the same pomegranate capsule might produce very different levels of active metabolites depending on the composition of their gut microbiome. It could partially explain why some individuals seem to respond to herbal treatments while clinical trials, which average results across diverse gut flora, show modest or null effects.
Herb-Drug Interactions Are a Real and Underappreciated Risk
For men already receiving conventional treatment for prostate cancer, adding herbal products is not a neutral decision. Research using animal models has shown that certain Chinese herbal medicines with androgenic properties can actually weaken the tumor-fighting effects of abiraterone, a drug commonly prescribed for advanced prostate cancer. These herbs appeared to increase androgen receptor expression and decrease the amount of abiraterone available in the bloodstream. In contrast, another herbal extract enhanced abiraterone’s anti-tumor effects by suppressing the androgen receptor and improving the drug’s bioavailability.26PubMed. Herb-drug interactions between androgenic Chinese herbal medicines and androgen receptor antagonist on tumor growth: Studies on two xenograft prostate cancer animal models
On the potentially helpful side, a standardized herbal extract studied in mice appeared to reduce the liver and kidney damage caused by docetaxel, a standard chemotherapy drug for prostate cancer, while simultaneously boosting its anti-tumor effect. Mice given the herb-chemo combination showed none of the liver cell death or kidney damage seen in mice receiving docetaxel alone.27Scientific Reports. A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer These findings, however, come from animal studies and cannot be directly applied to human dosing decisions. The broader lesson is that herbal products can interfere with cancer drugs in both directions, making some treatments less effective and others more toxic, which is why telling your oncologist about every supplement you are taking is non-negotiable.
Epigenetic Effects and Why They Matter
Beyond directly killing cancer cells, some plant polyphenols appear to influence how genes are expressed in prostate cancer. Various polyphenols have been shown to affect DNA methylation patterns, histone modifications, and microRNA expression in prostate cancer cells.28PubMed. The epigenetic potentials of dietary polyphenols in prostate cancer management These epigenetic changes can reactivate tumor-suppressor genes that the cancer had silenced or quiet genes that drive cancer growth. Genistein’s ability to reduce methylation of the estrogen receptor beta promoter, noted earlier, is one concrete example of this kind of activity.9PubMed Central. Genistein Increases Estrogen Receptor Beta Expression in Prostate Cancer via Reducing its Promoter Methylation
Epigenetic changes are theoretically reversible, unlike mutations in DNA itself, which makes them an attractive target. But the concentrations of polyphenols that produce these effects in a dish often far exceed what you could realistically achieve in prostate tissue by swallowing a capsule. Researchers are exploring whether long-term, low-level dietary exposure over years might produce cumulative epigenetic effects, but that is a hypothesis rather than something that has been demonstrated in a clinical trial. The prevention angle, eating polyphenol-rich foods over a lifetime to keep prostate cells behaving normally, may turn out to be more relevant than the treatment angle of taking high-dose supplements after a cancer diagnosis.
What Can Go Wrong with Supplement Quality
The PC-SPES contamination case was extreme, but it was not an isolated incident. Dietary supplements in the United States are regulated very differently from pharmaceutical drugs. Manufacturers do not need to prove that their products work before selling them, and the FDA’s ability to test products or enforce quality standards is limited. Issues with misidentified plant species, variable concentrations of active compounds from batch to batch, contamination with heavy metals or pesticides, and adulteration with undeclared pharmaceutical ingredients have been documented across the supplement industry.29PubMed Central. Nutraceuticals in Prostate Disease: The Urologist’s Role When you buy a pomegranate extract or curcumin capsule, the amount of active compound in the product may differ substantially from what is on the label. Third-party testing programs exist, and looking for products verified by organizations like USP or NSF International can reduce but not eliminate these risks.
This issue matters in a way that is specific to the herbal cancer research problem. If clinical trials use a carefully standardized extract and show a modest benefit, that result may not translate to a commercially available supplement with a different chemical profile. Conversely, if a trial shows no benefit, it is possible that the extract tested simply lacked sufficient quantities of the active compound. The variability in plant-derived products introduces noise into every study and makes it harder to draw clean conclusions, compounding the already substantial challenge of demonstrating clinical benefit.